Partial digestion
Gluten fragments remain immunologically relevant after digestion and reach the mucosal environment.
Next-generation coeliac disease research
Allosteric TG2 inhibition designed to make gluten peptides less immunogenic.
Glutopia Pharmaceuticals is developing GLT-201, a fictional oral small-molecule concept designed to engage the GTP-binding pocket of tissue transglutaminase 2 and stabilize TG2 in an inactive conformation.
GLT-201Lead concept
Pre-clinicalDiscovery stage
GLTPFictional ticker
Allosteric TG2
Gut-focused design
SwissADME-guided optimization
Investor-ready narrative
Mission statement
We design precise, gut-focused therapies that may help protect coeliac patients from accidental gluten exposure.
Our mission is to develop innovative, locally acting small molecules that reduce the immunogenicity of gluten peptides while minimizing unnecessary interference with TG2’s normal physiological roles.
With GLT-201, we focus on an allosteric approach: instead of blocking the active site of TG2, we explore the regulatory GTP-binding pocket to modulate enzyme activity more selectively.
The science
From gluten fragment to inflammatory cascade
Normally, gluten proteins are only partially digested in the intestine. TG2 can deamidate these gluten fragments, making them bind more strongly to HLA-DQ2 or HLA-DQ8 on antigen-presenting cells. This stronger binding can activate gluten-specific CD4+ T cells, stimulate B-cell antibody responses, and contribute to intestinal damage.
TG2 deamidation
TG2 chemically modifies gliadin/gluten peptides, which can increase their binding to HLA molecules.
HLA-DQ2/DQ8 presentation
Antigen-presenting cells present the modified fragments to gluten-specific CD4+ T cells.
Inflammatory response
T-cell activation strengthens the autoimmune response and can contribute to intestinal injury.
GLT-201 concept
Why allosteric instead of active-site inhibition?
ZED1227 supports TG2 as a therapeutic target, but active-site inhibition may raise selectivity and systemic off-target concerns because TG2 is expressed across the body and has physiological roles such as wound healing and tissue remodeling. GLT-201 therefore explores a different idea: allosteric stabilization through the GTP-binding pocket.
Design hypothesis
If TG2 is stabilized in its inactive GTP-bound-like conformation, gluten peptides may become less immunogenic, weakening T-cell activation and the downstream autoimmune response.
Supporting evidence
We use the PoseView figure and SwissADME output as supporting evidence for the concept story. Switch between both views and click the hotspots for the key findings extracted from your images.
Investor thesis
A differentiated mechanism with a clean strategic story.
Current care relies heavily on strict gluten avoidance. Glutopia’s fictional investment case is built around a differentiated mechanism, a clear biomarker rationale, and a molecule optimization strategy aimed at local intestinal activity.
Target rationaleTG2 remains a biologically validated node in coeliac disease.
Strategic differentiationAllosteric modulation may offer a route distinct from active-site inhibition.
Optimization pathSwissADME insights highlight where medicinal chemistry should focus next.